source
- Viking Therapeutics reports obesity drug maintains weight loss after dosing switch, shares jump 36%Viking Therapeutics said its Phase 2 trial of the dual-acting obesity candidate VK2735 showed participants largely kept the weight they had lost when the dosing schedule changed from a weekly injec…
- Boston life-science lab vacancy climbs to 31% as new spaces sit emptyVacancy rates for laboratory and manufacturing space in Massachusetts have surged dramatically, rising from around 3% in 2021 to roughly 31% by mid-2026, according to recent data. One high-profile…